Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors

NCT05256381 is registered in ClinicalTrials.gov with SOTIO Biotech AG as lead sponsor.

NCT NCT05256381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05256381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors
Lead sponsor
SOTIO Biotech AG
Phase
Phase 2
Overall status
Terminated
Start date
June 21, 2022
Completion date
November 29, 2024
Enrollment
166 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, colorectal cancer, cutaneous squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer